SNY
Sanofi Healthcare - Pharmaceuticals Investor Relations →
Sanofi (SNY) closed at $42.48 as of 2026-09-18, trading 5.5% below its 200-week moving average of $44.97. This places SNY in the deep value zone. The stock is currently moving closer to the line, down from -4.8% last week. The 14-week RSI sits at 42, indicating neutral momentum.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.22 ratio) is neutral — neither side is clearly dominating.
Over the past 1215 weeks of data, SNY has crossed below its 200-week moving average 20 times. On average, these episodes lasted 13 weeks. Historically, investors who bought SNY at the start of these episodes saw an average one-year return of +11.3%.
With a market cap of $101.8 billion, SNY is a large-cap stock. The company generates a free cash flow yield of 6.2%, which is healthy. Return on equity stands at 5.7%. The stock trades at 1.3x book value.
Over the past 23.3 years, a hypothetical investment of $100 in SNY would have grown to $340, compared to $1191 for the S&P 500. SNY has returned 5.4% annualized vs 11.2% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -5% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: SNY vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After SNY Crosses Below the Line?
Across 20 historical episodes, buying SNY when it crossed below its 200-week moving average produced an average return of +7.7% after 12 months (median +13.0%), compared to +13.6% for the S&P 500 over the same periods. 75% of those episodes were profitable after one year. After 24 months, the average return was +22.1% vs +34.5% for the index.
Each line shows $100 invested at the moment SNY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices SNY would reach each dislocation threshold.
Dislocation Price Levels
Prices where SNY's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-10-30.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $40.19 | Unusually cheap — analysis point |
| Value | +1σ | $41.39 | Cheap vs. own history |
| Fair Value | +0σ | $42.67 | Historical mean behavior |
| Expensive | -1σ | $44.02 | Expensive vs. own history |
| Deep Expensive | -2σ | $45.47 | Unusually expensive — analysis point |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.14 | $1.20 | +5.6% |
| 2026-04-23 | $1.03 | $1.10 | +7.3% |
| 2026-01-29 | $0.85 | $0.91 | +7.4% |
| 2025-10-24 | $1.57 | $1.69 | +8.1% |
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from SNY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
SNY has crossed below its 200-week MA 20 times with an average 1-year return of +11.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2003 | Sep 2003 | 5 | 6.3% | +21.2% | +267.1% |
| Jan 2008 | Sep 2009 | 86 | 35.7% | -21.7% | +133.1% |
| Feb 2010 | Feb 2010 | 1 | 1.4% | +2.1% | +141.4% |
| Apr 2010 | Sep 2010 | 21 | 13.9% | +22.2% | +151.3% |
| Nov 2010 | Jan 2011 | 7 | 2.4% | +3.5% | +152.9% |
| Nov 2015 | Mar 2017 | 71 | 15.8% | -0.5% | +55.2% |
| Apr 2017 | Apr 2017 | 1 | 0.8% | -6.4% | +45.2% |
| Dec 2017 | Jan 2018 | 4 | 1.6% | +5.6% | +43.4% |
| Jan 2018 | Jul 2018 | 22 | 10.6% | +5.2% | +43.4% |
| Mar 2020 | Mar 2020 | 1 | 7.2% | +36.2% | +49.0% |
| Aug 2022 | Nov 2022 | 15 | 14.9% | +25.2% | +14.1% |
| Oct 2023 | Nov 2023 | 3 | 7.0% | +31.3% | +13.2% |
| Dec 2023 | Dec 2023 | 1 | 0.3% | +9.1% | +5.4% |
| Feb 2024 | Feb 2024 | 2 | 1.7% | +19.6% | +5.0% |
| Apr 2024 | Apr 2024 | 2 | 2.6% | +16.9% | +6.3% |
| Sep 2025 | Sep 2025 | 1 | 1.3% | N/A | -1.5% |
| Jan 2026 | Jan 2026 | 1 | 0.1% | N/A | -3.8% |
| Feb 2026 | Feb 2026 | 1 | 1.4% | N/A | -2.6% |
| Mar 2026 | Mar 2026 | 3 | 6.6% | N/A | +0.6% |
| Apr 2026 | Ongoing | 21+ | 5.5% | Ongoing | -2.7% |
| Average | 13 | — | +11.3% | — |
Frequently Asked Questions
Is SNY below its 200-week moving average?
Yes. As of 2026-09-18, Sanofi (SNY) is trading 5.5% below its 200-week moving average of $44.97. The current price is $42.48.
What is SNY's 200-week moving average price?
Sanofi's 200-week moving average is $44.97 as of 2026-09-18. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when SNY drops below its 200-week moving average?
SNY has crossed below its 200-week moving average 20 times in our data. On average, buying at that moment produced a one-year return of +11.3%. These dips have historically been decent entry points. These episodes lasted 13 weeks on average.
Is SNY a good value right now?
Here's what our data says about SNY as of 2026-09-18: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 42. Free cash flow yield is 6.2%. Return on equity is 5.7%. Price-to-book is 1.3x. This is not a buy or sell recommendation — always do your own research.
How does SNY compare to the S&P 500?
Over the past 23.3 years, $100 invested in SNY would have grown to $340, compared to $1191 for the S&P 500. That's 5.4% annualized vs 11.2% for the index. SNY has underperformed the broader market over this period.
Does SNY pay a dividend?
Yes. Sanofi currently pays a dividend yield of 570.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-09-18